Barclays’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Barclays’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-813,800	Closed	-$19.8M	–	5271
2023 Q1	$19.8M	Buy	+813,800	New	+$17.8M	0.01%	843
2017 Q1	–	Sell	-149,200	Closed	-$721K	–	7061
2016 Q4	$721K	Buy	149,200 +83,900	+128%	+$2.49M	﹤0.01%	3050
2016 Q3	$3.01M	Buy	65,300 +55,300	+553%	+$3.12M	﹤0.01%	1669
2016 Q2	$510K	Buy	+10,000	New	+$497K	﹤0.01%	3199

Barclays's ISEE Position: Q3 2023 in Review

Barclays sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 235,648 shares — an estimated $9.27M sold.

Barclays first reported a position in ISEE in Q4 2013 and held it in 33 quarters. The position peaked at $17.5M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

Barclays reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Barclays sold 235,648 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $9.27M.
Barclays first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 33 quarters.
Barclays's IVERIC bio, Inc. Common Stock position peaked at $17.5M in Q1 2023.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.